USPTO serial 98390865
NEBULA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- VELTEN, MALLORY KATE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NEBULA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biological, and biochemical products for industrial and scientific purposes, other than for medical purposes, namely, biological cell cultures for scientific research purposes and not for medical or veterinary purposes; chemical products, namely, chemical additives for use in separation processes for biological materials; chemical, biochemical, and diagnostic reagents for non-medical scientific and medical research laboratory use, namely, for use in cell separation, labeling chemical, biochemical, and diagnostic reagents, cell culture media for growing cells, tempering substances, and chemical and protein ingredients for the preparation of media; chemical, biochemical, and diagnostic reagents for non-medical scientific purposes for the processing, separation, isolation, enrichment, transduction, transfection, depletion, detection, screening, analysis, and counting of materials, namely, chemical materials and biological materials, especially biological cells; chemical, biochemical, and diagnostic reagents for non-medical scientific purposes with magnetic beads; antibody reagents with fluorescent molecules used for the detection of antigens in cells and tissue, other than for medical or veterinary purposes; chemical preparations for scientific purposes, namely, chemical buffer solutions and chemical reagents for use with laboratory instruments, especially separation instruments, analysis instruments, and reactor instruments; reagents for scientific purposes, namely, for processing of biological material, especially tissue, bone marrow, cells, and blood and its components, other than for medical or veterinary purposes; diagnostic reagents and diagnostic preparations for scientific purposes and for use in medical research laboratories; biological tissue cell culture media, cell culture media, and cryogenic chemical preparations for scientific purposes, namely, for use in the freezing of genetic and blood tissue; chemical, biochemical, and diagnostic reagents for non-medical scientific purposes, namely, for use in biotechnology, in biological treatment processes, and in the biotechnology industry | ACTIVE | — |
| 005 | Reagents for medical and veterinary use, namely, for the processing, separation, isolation, enrichment, transduction, transfection, depletion, detection, screening, analysis, and counting of material, especially of biological materials and biological cells; reagents with magnetic beads for medical and veterinary use; antibody reagents used for the detection of antigens in cells and tissue for medical purposes; disinfectants for medical instruments in the nature of buffer solutions and reagents for use with medical instruments, especially separation instruments, analysis instruments, and reactor instruments; reagents for medical and veterinary use, namely, for the processing of biological material, especially tissue, bone marrow, cells, and blood and its components; culture media for cultivating human, animal, and microorganism cells for medical purposes; diagnostic reagents and diagnostic preparations for medical and veterinary purposes; cryopreservation cell freezing media for medical and veterinary purposes; pharmaceutical products, namely, pharmaceutical preparations for the cellular therapy treatment of cancer, autoimmunity, infection, inflammation, tissue-based diseases, and immunological, dermatological, and neurological diseases; chemical, biological, and biochemical products for therapeutic and diagnostic purposes, namely, diagnostic preparations made from chemicals and biochemicals for medical purposes for the treatment of cancer, autoimmunity, and dermatological, neurological, and cardiovascular diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 15, 2025 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 15, 2025 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 25, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 25, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 24, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 24, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 12, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 17, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 17, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 28, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 13, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 9, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 9, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 9, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 3, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 3, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 3, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 11, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 7, 2024 | NWAP | NEW APPLICATION ENTERED | — |